Discover more from FarmaKology’s Substack

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me.

Over 10,000 subscribers

FarmaKology -Molecular Agent Designed To Image and Treat Tumors

FarmaKology

Oct 27, 2021

Today's Company

DNAe

DNAe is a pioneering molecular diagnostics company developing solutions which enable rapid near-patient, real-time diagnostics. The innovative application of DNAe’s semiconductor technology in LiDiaTM diagnostic products allows us to combine powerful analytical capability and accurate results with speed and simplicity, while performing a range of genomic analyses –from highly parallel separate tests to powerful next generation sequencing (NGS). And in every scenario, it is a complete end-to-end diagnostic solution for a fast actionable result.DNAe’s initial focus is on a diagnostic test for bloodstream infections for use in the management and prevention of sepsis where speed can make the difference between life and death. By accurately and rapidly identifying what infection a patient has, the test will provide the clinician with the actionable information needed to help select the appropriate antibiotics to treat the disease.Founded in 2003, and headquartered in London, UK, DNAe has expanded operations further in 2015 with a clinical diagnostic development and manufacturing site in San Diego, CA. Our company employs over 100 people and we are always on the look out for exceptional talent.

News

Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases

Vertex Pharmaceuticals Incorporated and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems.

Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma

Novartis today announced that the US Food and Drug Administration and the European Medicines Agency have accepted the company’s Supplemental Biologics License Application (sBLA) and Type II Variation, respectively, for Kymriah® (tisagenlecleucel) in adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two prior lines of treatment. The FDA has also granted priority review to the company’s sBLA for Kymriah in adult patients with r/r FL. Kymriah was previously granted orphan medicinal product designation by the European Commission for FL.

LOVE Pharma Announces Debut of New Products, BLOOM™ and AURALIEF™

LOVE Pharma Co. , the Company is pleased to announce the debut of its first two products, BLOOM™ and AURALIEF™. Zachary Stadnyk, CEO and Director, stated: “It is with great excitement that we are able to announce the launch of our first two fully-branded products, Bloom and Auralief. We believe these two products within our strong portfolio of intellectual property can quickly command significant market share in the shortest period. We look forward to updating our investors as we progress through the rollout of these first two products and subsequently, the company’s therapeutic and wellness products in a strategic, staggered approach”.

U.S. FDA advisers back Pfizer/BioNTech COVID-19 vaccine for children

An expert panel on Tuesday voted overwhelmingly to recommend the U.S. Food and Drug Administration authorize the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages 5 to 11, saying the benefits of the shot outweigh the risks. An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.